Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1989 Dec;86(24):10108–10112. doi: 10.1073/pnas.86.24.10108

Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.

P E Hallaway 1, J W Eaton 1, S S Panter 1, B E Hedlund 1
PMCID: PMC298654  PMID: 2481311

Abstract

A class of high molecular weight iron chelators has been prepared by covalently attaching deferoxamine (DFO), by its amino group, to a variety of biocompatible polymers such as dextran and hydroxyethyl-starch. The iron-binding properties of DFO are virtually unchanged after the attachment procedure, but the toxicity and circulatory half-life are profoundly altered. Competitive iron-binding experiments indicate that the conjugates retain a high affinity for ferric iron. In addition, the derivatives inhibit iron-driven lipid peroxidation as effectively as the parent drug. However, the LD50 in mice (based on DFO equivalents) is approximately 4000 mg/kg for dextran-DFO as compared to 250 mg/kg for free DFO. Consistent with the greatly decreased LD50, intravenous administration of the conjugates in dogs at a dose of 100 mg/kg (body weight) does not cause the severe hypotension associated with intravenous administration of DFO. The plasma half-lives of these adducts are increased greater than 10-fold for dextran-DFO and hydroxyethyl-starch-DFO compared to the free drug. Finally, and most importantly, the conjugates are effective in mediating in vivo iron mobilization and excretion. Because recent evidence implicates iron as an important component of tissue injury in many disease states, these high molecular weight iron chelators may have potential for improved therapy, allowing higher sustained plasma concentrations of the active drug.

Full text

PDF
10108

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosio G., Zweier J. L., Jacobus W. E., Weisfeldt M. L., Flaherty J. T. Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. Circulation. 1987 Oct;76(4):906–915. doi: 10.1161/01.cir.76.4.906. [DOI] [PubMed] [Google Scholar]
  2. Artiss J. D., Vinogradov S., Zak B. Spectrophotometric study of several sensitive reagents for serum iron. Clin Biochem. 1981 Dec;14(6):311–315. doi: 10.1016/s0009-9120(81)91065-1. [DOI] [PubMed] [Google Scholar]
  3. Bolli R., Patel B. S., Zhu W. X., O'Neill P. G., Hartley C. J., Charlat M. L., Roberts R. The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction. Am J Physiol. 1987 Dec;253(6 Pt 2):H1372–H1380. doi: 10.1152/ajpheart.1987.253.6.H1372. [DOI] [PubMed] [Google Scholar]
  4. Buege J. A., Aust S. D. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310. doi: 10.1016/s0076-6879(78)52032-6. [DOI] [PubMed] [Google Scholar]
  5. Cohen A., Schwartz E. Iron chelation therapy with deferoxamine in Cooley anemia. J Pediatr. 1978 Apr;92(4):643–647. doi: 10.1016/s0022-3476(78)80314-x. [DOI] [PubMed] [Google Scholar]
  6. Emery T. Exchange of iron by gallium in siderophores. Biochemistry. 1986 Aug 12;25(16):4629–4633. doi: 10.1021/bi00364a026. [DOI] [PubMed] [Google Scholar]
  7. Farber N. E., Vercellotti G. M., Jacob H. S., Pieper G. M., Gross G. J. Evidence for a role of iron-catalyzed oxidants in functional and metabolic stunning in the canine heart. Circ Res. 1988 Aug;63(2):351–360. doi: 10.1161/01.res.63.2.351. [DOI] [PubMed] [Google Scholar]
  8. Graf E., Mahoney J. R., Bryant R. G., Eaton J. W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J Biol Chem. 1984 Mar 25;259(6):3620–3624. [PubMed] [Google Scholar]
  9. Gutteridge J. M., Richmond R., Halliwell B. Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine. Biochem J. 1979 Nov 15;184(2):469–472. doi: 10.1042/bj1840469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. KEBERLE H. THE BIOCHEMISTRY OF DESFERRIOXAMINE AND ITS RELATION TO IRON METABOLISM. Ann N Y Acad Sci. 1964 Oct 7;119:758–768. doi: 10.1111/j.1749-6632.1965.tb54077.x. [DOI] [PubMed] [Google Scholar]
  11. Mahoney J. R., Jr, Hallaway P. E., Hedlund B. E., Eaton J. W. Acute iron poisoning. Rescue with macromolecular chelators. J Clin Invest. 1989 Oct;84(4):1362–1366. doi: 10.1172/JCI114307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Olivieri N. F., Buncic J. R., Chew E., Gallant T., Harrison R. V., Keenan N., Logan W., Mitchell D., Ricci G., Skarf B. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986 Apr 3;314(14):869–873. doi: 10.1056/NEJM198604033141402. [DOI] [PubMed] [Google Scholar]
  13. Pitt C. G., Gupta G., Estes W. E., Rosenkrantz H., Metterville J. J., Crumbliss A. L., Palmer R. A., Nordquest K. W., Hardy K. A., Whitcomb D. R. The selection and evaluation of new chelating agents for the treatment of iron overload. J Pharmacol Exp Ther. 1979 Jan;208(1):12–18. [PubMed] [Google Scholar]
  14. Propper R. D., Cooper B., Rufo R. R., Nienhuis A. W., Anderson W. F., Bunn H. F., Rosenthal A., Nathan D. G. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25;297(8):418–423. doi: 10.1056/NEJM197708252970804. [DOI] [PubMed] [Google Scholar]
  15. Stocks J., Gutteridge J. M., Sharp R. J., Dormandy T. L. Assay using brain homogenate for measuring the antioxidant activity of biological fluids. Clin Sci Mol Med. 1974 Sep;47(3):215–222. doi: 10.1042/cs0470215. [DOI] [PubMed] [Google Scholar]
  16. Summers M. R., Jacobs A., Tudway D., Perera P., Ricketts C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol. 1979 Aug;42(4):547–555. doi: 10.1111/j.1365-2141.1979.tb01167.x. [DOI] [PubMed] [Google Scholar]
  17. Westlin W. F. Deferoxamine in the treatment of acute iron poisoning. Clinical experiences with 172 children. Clin Pediatr (Phila) 1966 Sep;5(9):531–535. doi: 10.1177/000992286600500907. [DOI] [PubMed] [Google Scholar]
  18. Whitten C. F., Chen Y. C., Gibson G. W. Studies in acute iron poisoning. II. Further observations on desferrioxamine in the treatment of acute experimental iron poisoning. Pediatrics. 1966 Jul;38(1):102–110. [PubMed] [Google Scholar]
  19. Whitten C. F., Gibson G. W., Good M. H., Goodwin J. F., Brough A. J. Studies in acute iron poisoning. I. Desferrioxamine in the treatment of acute iron poisoning: clinical observations, experimental studies, and theoretical considerations. Pediatrics. 1965 Sep;36(3):322–335. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES